has been carried out in Germany since 1971. The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer, as the guideline aims to provide important information and support for planned organized screening for cervical cancer in Germany.
Methods With the financial support of German Cancer Aid, 21 professional societies developed evidence-based statements and recommendations (classified using the GRADE system) for the screening, management and treatment of pre-cancerous conditions of the cervix. Two independent scientific institutes compiled systematic reviews for this guideline.
Recommendations The first part of this short summary presents the pathological basis and considers various questions related to screening for cervical cancer. As also reported in earlier reviews, the meta-analysis by Kleijnen Systematic Reviews showed that HPV-based screening offers better protection against invasive cervical cancer compared to cytologybased screening. The authors of this guideline therefore recommendin accordance with the guideline of the Joint National Committee of Germany (Gemeinsamer Bundesauschuss, G-BA)that women aged 35 and above should be examined at regular intervals (at least every 3 years) and undergo HPV-based screening. Co-testing can also be carried out. Women between the ages of 20 
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which participated in developing the guideline together with their respective mandated representatives. Only mandate holders nominated by participating societies and organizations were eligible to vote on a chapter-by-chapter basis during the voting process (consensus process) after they had disclosed and excluded any conflicts of interest. A patient representative was directly involved in the compilation of this guideline. Ms. Marion Gebhardt (Frauenselbsthilfe nach Krebs e. V. [Self-help for Women After Cancer]) was involved in developing the guideline right from the start and attended the consensus conferences where she had voting rights.
II
Guideline Application
Purpose and objectives
The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer. The S3 guideline provides important information and support for the planned organized screening for cervical cancer in Germany.
The old S2k German-language guideline "Prevention, Diagnosis and Therapy of HPV Infections and Preinvasive Lesions of the Female Genitalia" was consulted, with the new guideline focusing on those aspects which deal with the cervix. The guideline recommendations for primary prevention were adopted from the updated S3 guideline on HPV vaccination and supplemented by additional information regarding the impact of HPV vaccination on screening. The S3 guideline on the Diagnosis and Therapy of Cervical Cancer published in 2014 covers all aspects of invasive cervical cancer.
Targeted areas of patient care
This S3 guideline on the prevention of cervical cancer covers the prevention of cervical cancer and the diagnosis, treatment and follow-up of cervical cancer including high-grade preinvasive cervical lesions. The most important goals of the guideline were analyzing the existing data to optimize screening for cervical cancer in terms of determining the optimal test procedures, organization, investigative algorithm and treatment and considering the question of how to encourage women who refuse to go for screening to participate in the program. In addition, the guideline investigated the impact of HPV vaccination on the screening strategy for cervical cancer.
Target patient groups
This S3 guideline is aimed at all women aged 20 and above.
Target user groups/target audience
The recommendations of the guideline are addressed to all physicians and professionals involved in screening for cervical cancer, in particular gynecologists, pathologists and cytologists, as well as all healthcare professionals working in dysplasia outpatient clinics and centers.
Other target groups include: ▪ scientific medical societies and professional associations which are involved in screening for cervical cancer, ▪ womenʼs advocacy groups (womenʼs health organizations, patient and self-help organizations), ▪ quality assurance organizations and similar projects on national and federal state levels, ▪ healthcare policy institutions and decision-makers at national and federal state levels, ▪ payers, ▪ the general public to inform them about what constitutes a good medical approach.
Adoption and period of validity
This guideline is valid from 31 December 2017 through to 31 December 2020. Because of the contents of the guideline, this period of validity is only an estimate. The guideline may need to be updated if new scientific evidence appears or the methodology used in the guideline is developed further. Moreover, the key statements and recommendations of the guideline should be subjected to regular editorial checks, and the contents of the guideline should be reviewed regularly.
III Methodology

Basic principles
The method used to prepare this guideline was determined by the class to which this guideline was assigned. The AWMF Guidance Manual (version 1.0) has set out the respective rules and requirements for different classes of guidelines. Guidelines are differentiated into lowest (S1), intermediate (S2) and highest (S3) class. The lowest class is defined as a set of recommendations for action compiled by a non-representative group of experts. In 2004, the S2 class was divided into two subclasses: a systematic evidencebased subclass (S2e) and a structural consensus-based subclass (S2k). The highest S3 class combines both approaches. This guideline is classified as: S3.
Grading of evidence
The GRADE (GRADE = Grading of Recommendations Assessment, Development and Evaluation) system developed by the GRADE Working Group [1] (www.gradeworkinggroup.org) was used to evaluate the quality of evidence of the studies identified and used for this guideline (▶ Table 2 ).
▶ Table 2 Grading of quality of evidence based on the GRADE system.
GRADE Description Symbol
High quality "We are very confident that the true effect lies close to that of the estimate of the effect."
⊕⊕⊕⊕
Moderate quality
"We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different."
⊕⊕⊕⊖
Low quality
"Our confidence in the effect estimate is limited:
The true effect may be substantially different from the estimate of the effect."
⊕⊕⊖⊖
Very low quality
"We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect."
⊕⊖⊖⊖
Grading of recommendations
The methodology of the Oncology Guidelines Program requires guideline authors to assign a level of recommendation to each recommendation indicating the strength of the recommendation. The strength of each recommendation is agreed upon during a formal consensus process which requires structured consensus conferences [2] . (Details are available from the German-language Guideline Report). As part of the process, mandate holders with voting rights formally voted on the recommendations of this guideline. This guideline includes information on the grading of the evidence of the underlying studies used for all evidence-based Statements and Recommendations and additionally shows the strength of each recommendation (level of recommendation). As outlined in the AWMF Guidance Manual [2] , this guideline differentiates between three strengths or levels of recommendation, and the respective level of recommendation is reflected by the syntax used in the recommendation (▶ Table 3 ).
The decision criteria used to determine the level of recommendation are explained in the German-language Guideline Report for this guideline.
Statements
Statements are expositions or explanations of specific facts, circumstances, or problems, with no direct recommendations for action. Statements are adopted after a formal consensus process using the same approach as that used when formulating recommendations and can be based either on study results or expert opinions (▶ Table 4 : Level of consensus).
Expert consensus (EC)
Statements/Recommendations which were based on the expert consensus of the guideline authors are marked as expert consensus. No symbols or letters were used to grade the expert consensus; the respective level of consensus is shown by the syntax used (must/should/may) based on the differentiation described in ▶ Table 3 .
IV Guideline 1 Pathological, Cytological and Virological Basis 2 Epidemiology
Cervical cancer is the third most common cancer in women worldwide. The incidence and mortality rates vary considerably. Particularly in less developed countries, many women still die from cervical cancer every year. In Germany, the incidence rate standardized for age (European standard) was 9.3 per 100 000 in 2012. The actual raw incidence rate for Germany in 2012 was 11.3 per 100 000. The introduction of cancer screening using Pap smears in 1971 contributed to a significant decrease in incidence and mortality rates in Germany. However, in recent years, incidence and mortality rates in Germany have stagnated.
Persistent infection with human papillomavirus is the main cause of cervical cancer. The prevalence of HPV is particularly high in young women under the age of 30. HPV 16 is the most common HPV type worldwide. HPV types 16 and 18 are responsible for 60 to 70 % of all cervical carcinomas.
3
Primary Prevention (HPV Vaccination)
The following items from the HPV vaccination guideline 082/002 [3] represent a summary of the recommendations made by the guideline authors.
▶ Table 3 Level of recommendation. In women aged 30 and above, organized screening programs based on an HPV test alone or an HPV test combined with cytology and carried out at regular intervals of 3 or 5 years lead to a significant reduction in the number of new cases with cervical cancer (6/100 000) in the second round of screening after three or five years compared to organized screening programs carried out at regular intervals of 3 or 5 years which are based on cytological screening alone (20/100 000; RR 0.29).
Level of recommendation
⊕⊖⊖⊖ [15, 43 -59] 7.4. In women aged 30 years and above, organized screening programs carried out at regular intervals of 3 or 5 years which are based on testing for HPV alone or testing for HPV combined with cytology lead to a significant reduction in the number of new cases with CIN 3+ (82/100 000) in the second round of screening after three or five years compared to organized screening programs carried out at regular intervals of 3 or 5 years which are based on cytological screening alone (159/100 000; RR 0.59).
⊕⊕⊕⊖ [15, 48 -61] No. Recommendations/Statements GRADE Sources
7.5.
There is no evidence that there is any difference in the level of psychological stress experienced by women who have HPV-based screening compared to women who have cytological screening every 3 years.
⊕⊕⊕⊖ [60, 61] No. Recommendations/Statements GRADE Sources 7.6. HPV-based screening and HPV test + cytology-based screening carried out every 3 or 5 years result in the detection of more cases with CIN 2 compared to cytology-based screening carried out every 3 or 5 years.
This also increases the risk of overdiagnosis and overtreatment in the population being screened. This disadvantage is particularly pronounced in women under the age of 30 years. Shorter intervals between screening examinations increase the risk of overdiagnosis and overtreatment. There is no evidence that cytological screening carried out annually is superior to cytological screening carried out every two years. EC 8.8. In Germany, during the transition period (at least another 6 years or until sufficient data is available from the 2nd round of screening) women between the age of 20 and 35 will still be entitled to have an annual cytological examination. After the end of the transition period, the intervals between screening appointments and the screening method itself must be adapted to conform to international recommendations after the data used to monitor this age group has been taken into account.
In future, women aged 35 and above will be offered a combined screening examination consisting of an HPV test and a cytological examination instead of an annual cytological examination every 3 years. 
